Biology subjects

Adolf-Bryfogle, J.

Publications and source records attributed to Adolf-Bryfogle, J..

7 recordsLinked to original sources

bioRxiv2023

EGGNet, a generalizable geometric deep learning framework for protein complex pose scoring

Computational prediction of molecule-protein interactions has been key for developing new molecules to interact with a target protein for therapeutics development. Past work includes two independent streams of approaches: (1) predicting protein-protein interactions (PPI) between naturally occurring proteins and (2) predicting the binding affinities between proteins and small molecule ligands (aka drug target interaction, or DTI). Studying the two problems in isolation has limited the ability of these computational models to generalize across the PPI and DTI tasks, both of which ultimately involve non-covalent interactions with a protein target. In this work, we developed an Equivariant Graph of Graphs neural Network (EGGNet), a geometric deep learning framework for molecule-protein binding predictions that can handle three types of molecules for interacting with a target protein: (1) small molecules, (2) synthetic peptides and (3) natural proteins. EGGNet leverages a graph of graphs (GoGs) representation constructed from the molecule structures at atomic-resolution and utilizes a multi-resolution equivariant graph neural network (GNN) to learn from such representations. In addition, EGGNet leverages the underlying biophysics and makes use of both atom- and residue-level interactions, which improve EGGNets ability to rank candidate poses from blind docking. EGGNet achieves competitive performance on both a public proteinsmall molecule binding affinity prediction task (80.2% top-1 success rate on CASF-2016) and an synthetic protein interface prediction task (88.4% AUPR). We envision that the proposed geometric deep learning framework can generalize to many other protein interaction prediction problems, such as binding site prediction and molecular docking, helping accelerate protein engineering and structure-based drug development.

synthetic biology↗

bioRxiv2022

A penultimate classification of canonical antibody CDR conformations

Antibody complementarity determining regions (CDRs) are loops within antibodies responsible for engaging antigens during the immune response and in antibody therapeutics and laboratory reagents. Since the 1980s, the conformations of the hypervariable CDRs have been structurally classified into a number of "canonical conformations" by Chothia, Lesk, Thornton, and others. In 2011 (North et al, J Mol Biol. 2011), we produced a quantitative clustering of approximately 300 structures of each CDR based on their length, a dihedral angle metric, and an affinity propagation algorithm. The data have been made available on our PyIgClassify website since 2015 and have been widely used in assigning conformational labels to antibodies in new structures and in molecular dynamics simulations. In the years since, it is has become apparent that many of the clusters are not "canonical" since they have not grown in size and still contain few sequences. Some clusters represent multiple conformations, given the assignment method we have used since 2015. Electron density calculations indicate that some clusters are due to misfitting of coordinates to electron density. In this work, we have performed a new statistical clustering of antibody CDR conformations. We used Electron Density in Atoms (EDIA, Meyder et al., 2017) to produce data sets with different levels of electron density validation. Clusters were chosen by their presence in high electron density cutoff data sets and with sufficient sequences ([≥]10) across the entire PDB (no EDIA cutoff). About half of the North et al. clusters have been "retired" and 13 new clusters have been identified. We also include clustering of the H4 and L4 CDRs, otherwise known as the "DE loop" which connects strands D and E of the variable domain. The DE loop sometimes contacts antigens and affects the structure of neighboring CDR1 and CDR2 loops. The current database contains 6,486 PDB antibody entries. The new clustering will be useful in the analysis and development of new antibody structure prediction and design algorithms based on rapidly emerging techniques in deep learning. The new clustering data are available at http://dunbrack2.fccc.edu/PyIgClassify2.

immunology↗

bioRxiv2021

Growing Glycans in Rosetta: Accurate de novo glycan modeling, density fitting, and rational sequon design

Carbohydrates and glycoproteins modulate key biological functions. Computational approaches inform function to aid in carbohydrate structure prediction, structure determination, and design. However, experimental structure determination of sugar polymers is notoriously difficult as glycans can sample a wide range of low energy conformations, thus limiting the study of glycan-mediated molecular interactions. In this work, we expanded the RosettaCarbohydrate framework, developed and benchmarked effective tools for glycan modeling and design, and extended the Rosetta software suite to better aid in structural analysis and benchmarking tasks through the SimpleMetrics framework. We developed a glycan-modeling algorithm, GlycanTreeModeler, that computationally builds glycans layer-by-layer, using adaptive kernel density estimates (KDE) of common glycan conformations derived from data in the Protein Data Bank (PDB) and from quantum mechanics (QM) calculations. After a rigorous optimization of kinematic and energetic considerations to improve near-native sampling enrichment and decoy discrimination, GlycanTreeModeler was benchmarked on a test set of diverse glycan structures, or "trees". Structures predicted by GlycanTreeModeler agreed with native structures at high accuracy for both de novo modeling and experimental density-guided building. GlycanTreeModeler algorithms and associated tools were employed to design de novo glycan trees into a protein nanoparticle vaccine that are able to direct the immune response by shielding regions of the scaffold from antibody recognition. This work will inform glycoprotein model prediction, aid in both X-ray and electron microscopy density solutions and refinement, and help lead the way towards a new era of computational glycobiology.

molecular biology↗

bioRxiv2021

Ensuring scientific reproducibility in bio-macromolecular modeling via extensive, automated benchmarks

Each year vast international resources are wasted on irreproducible research. The scientific community has been slow to adopt standard software engineering practices, despite the increases in high-dimensional data, complexities of workflows, and computational environments. Here we show how scientific software applications can be created in a reproducible manner when simple design goals for reproducibility are met. We describe the implementation of a test server framework and 40 scientific benchmarks, covering numerous applications in Rosetta bio-macromolecular modeling. High performance computing cluster integration allows these benchmarks to run continuously and automatically. Detailed protocol captures are useful for developers and users of Rosetta and other macromolecular modeling tools. The framework and design concepts presented here are valuable for developers and users of any type of scientific software and for the scientific community to create reproducible methods. Specific examples highlight the utility of this framework and the comprehensive documentation illustrates the ease of adding new tests in a matter of hours.

bioinformatics↗

bioRxiv2021

Biochemical and Structural Characterization of Two Cif-Like Epoxide Hydrolases from Burkholderia cenocepacia

Epoxide hydrolases catalyze the conversion of epoxides to vicinal diols in a range of cellular processes such as signaling, detoxification, and virulence. These enzymes typically utilize a pair of tyrosine residues to orient the substrate epoxide ring in the active site and stabilize the hydrolysis intermediate. A new subclass of epoxide hydrolases that utilize a histidine in place of one of the tyrosines was established with the discovery of the CFTR Inhibitory Factor (Cif) from Pseudomonas aeruginosa. Although the presence of such Cif-like epoxide hydrolases was predicted in other opportunistic pathogens based on sequence analyses, only Cif and its homologue aCif from Acinetobacter nosocomialis have been characterized. Here we report the biochemical and structural characteristics of Cfl1 and Cfl2, two Cif-like epoxide hydrolases from Burkholderia cenocepacia. Cfl1 is able to hydrolyze xenobiotic as well as biological epoxides that might be encountered in the environment or during infection. In contrast, Cfl2 shows very low activity against a diverse set of epoxides. The crystal structures of the two proteins reveal quaternary structures that build on the well-known dimeric assembly of the /{beta} hydrolase domain, but broaden our understanding of the structural diversity encoded in novel oligomer interfaces. Analysis of the interfaces reveals both similarities and key differences in sequence conservation between the two assemblies, and between the canonical dimer and the novel oligomer interfaces of each assembly. Finally, we discuss the effects of these higher-order assemblies on the intra-monomer flexibility of Cfl1 and Cfl2 and their possible roles in regulating enzymatic activity.

biochemistry↗

bioRxiv2020

Hiding in plain sight: structure and sequence analysis reveals the importance of the antibody DE loop for antibody-antigen binding.

Antibody variable domains contain "complementarity determining regions" (CDRs), the loops that form the antigen binding site. CDRs1-3 are recognized as the canonical CDRs. However, a fourth loop sits adjacent to CDR1 and CDR2 and joins the D and E strands on the antibody v-type fold. This "DE loop" is usually treated as a framework region, even though mutations in the loop affect the conformation of the CDRs and residues in the DE loop occasionally contact antigen. We analyzed the length, structure, and sequence features of all DE loops in the Protein Data Bank, as well as millions of sequences from HIV-1 infected and naive patients. We refer to the DE loop as H4 and L4 in the heavy and light chain respectively. Clustering the backbone conformations of the most common length of L4 (6 residues) reveals four conformations: two {kappa}-only clusters, one {lambda}-only cluster, and one mixed {kappa}/{lambda} cluster. The vast majority of H4 loops are length-8 and exist primarily in one conformation; a secondary conformation represents a small fraction of H4-8 structures. H4 sequence variability exceeds that of the antibody framework in naive human high-throughput sequences, and both L4 and H4 sequence variability from {lambda} and heavy germline sequences exceed that of germline framework regions. Finally, we identified dozens of structures in the PDB with insertions in the DE loop, all related to broadly neutralizing HIV-1 antibodies, as well as antibody sequences from high-throughput sequencing studies of HIV-infected individuals, illuminating a possible role in humoral immunity to HIV-1.

bioinformatics↗

bioRxiv2017

Rosetta Antibody Design (RAbD): A General Framework for Computational Antibody Design

A structural-bioinformatics-based computational methodology and framework have been developed for the design of antibodies to targets of interest. RosettaAntibodyDesign (RAbD) samples the diverse sequence, structure, and binding space of an antibody to an antigen in highly customizable protocols for the design of antibodies in a broad range of applications. The program samples antibody sequences and structures by grafting structures from a widely accepted set of the canonical clusters of CDRs (North et al., J. Mol. Biol., 406:228-256, 2011). It then performs sequence design according to amino acid sequence profiles of each cluster, and samples CDR backbones using a flexible-backbone design protocol incorporating cluster-based CDR constraints. Starting from an existing experimental or computationally modeled antigen-antibody structure, RAbD can be used to redesign a single CDR or multiple CDRs with loops of different length, conformation, and sequence. We rigorously benchmarked RAbD on a set of 60 diverse antibody-antigen complexes, using two design strategies - optimizing total Rosetta energy and optimizing interface energy alone. We utilized two novel metrics for measuring success in computational protein design. The design risk ratio (DRR) is equal to the frequency of recovery of native CDR lengths and clusters divided by the frequency of sampling of those features during the Monte Carlo design procedure. Ratios greater than 1.0 indicate that the design process is picking out the native more frequently than expected from their sampled rate. We achieved DRRs for the non-H3 CDRs of between 2.4 and 4.0. The antigen risk ratio (ARR) is the ratio of frequencies of the native amino acid types, CDR lengths, and clusters in the output decoys for simulations performed in the presence and absence of the antigen. For CDRs, we achieved cluster ARRs as high as 2.5 for L1 and 1.5 for H2. For sequence design simulations without CDR grafting, the overall recovery for the native amino acid types for residues that contact the antigen in the native structures was 72% in simulations performed in the presence of the antigen and 48% in simulations performed without the antigen, for an ARR of 1.5. For the non-contacting residues, the ARR was 1.08. This shows that the sequence profiles are able to maintain the amino acid types of these conserved, buried sites, while recovery of the exposed, contacting residues requires the presence of the antigen-antibody interface. We tested RAbD experimentally on both a lambda and kappa antibody-antigen complex, successfully improving their affinities 10 to 50 fold by replacing individual CDRs of the native antibody with new CDR lengths and clusters.\n\nAuthor SummaryAntibodies are proteins produced by the immune system to attack infections and cancer and are also used as drugs to treat cancer and autoimmune diseases. The mechanism that has evolved to produce them is able to make 10s of millions of different antibodies, each with a different surface used to bind the foreign or mutated molecule. We have developed a method to design antibodies computationally, based on the 1000s of experimentally determined three-dimensional structures of antibodies available. The method works by treating pieces of these structures as a collection of parts that can be combined in new ways to make better antibodies. Our method has been implemented in the protein modeling program Rosetta, and is called RosettaAntibodyDesign (RAbD). We tested RAbD both computationally and experimentally. The experimental test shows that we can improve existing antibodies by 10 to 50 fold, paving the way for design of entirely new antibodies in the future.

bioengineering↗